/NVO
NVO Stock - Novo Nordisk A/S
Healthcare|Drug Manufacturers - GeneralNYSE
$48.09+1.01%
+$0.48 (+1.01%) • Dec 19
57
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.15
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).68
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+8.8%upside
Target: $52.32
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NVO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$47.61 – $48.57
TARGET (TP)$52.33
STOP LOSS$44.24
RISK/REWARD1:1.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.35
52W High$93.80
52W Low$43.08
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $290.40B | $232.26B | $176.95B | $140.80B | $126.95B |
| Gross Profit | $245.88B | $196.50B | $148.51B | $117.14B | $106.01B |
| Gross Margin | 84.7% | 84.6% | 83.9% | 83.2% | 83.5% |
| Operating Income | $128.34B | $102.57B | $74.81B | $58.64B | $54.13B |
| Net Income | $100.99B | $83.68B | $55.52B | $47.76B | $42.14B |
| Net Margin | 34.8% | 36.0% | 31.4% | 33.9% | 33.2% |
| EPS | $22.67 | $18.67 | $12.26 | $10.40 | $9.03 |
Company Overview
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
11
48%
Hold / Neutral
10
43%
Sell / Underperform
2
9%
Analyst Consensus🔴 Bearish
11 Bullish12 Neutral/Bearish
Price Targets
$102
Average Target
↑ 112.3% Upside
Now
$47
Low
$102
Average
$163
High
Based on 10 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 8th 2025 | Argus | Downgrade | Hold | - |
| October 27th 2025 | Jefferies | Resumed | Underperform | - |
| October 1st 2025 | HSBC Securities | Upgrade | Buy | - |
| September 29th 2025 | Morgan Stanley | Downgrade | Underweight | $47 |
| September 17th 2025 | Berenberg | Upgrade | Buy | - |
| September 16th 2025 | Rothschild & Co Redburn | Upgrade | Buy | - |
| September 9th 2025 | Bernstein | Upgrade | Outperform | - |
| August 13th 2025 | BNP Paribas Exane | Upgrade | Neutral | $54 |
| August 5th 2025 | UBS | Downgrade | Neutral | - |
| July 31st 2025 | HSBC Securities | Downgrade | Hold | $57 |
| July 30th 2025 | Barclays | Downgrade | Equal Weight | - |
| April 17th 2025 | BMO Capital Markets | Downgrade | Market Perform | $64 |
| March 13th 2025 | Kepler | Upgrade | Buy | - |
| March 3rd 2025 | Stifel | Downgrade | Hold | - |
| February 12th 2025 | Morgan Stanley | Initiation | Equal Weight | - |
Earnings History & Surprises
NVOBeat Rate
61%
Last 18 quarters
Avg Surprise
+4.5%
EPS vs Estimate
Beats / Misses
11/3
4 met exactly
Latest EPS
$1.02
Q4 2025
EPS Surprise History
Q1 24
+9.5%
$0.71vs$0.65
Q2 24
+10.5%
$0.82vs$0.74
Q3 24
-5.9%
$0.66vs$0.70
Q4 24
+1.4%
$0.88vs$0.87
Q1 25
+3.4%
$0.91vs$0.88
Q2 25
0.0%
$0.92vs$0.92
Q3 25
+4.3%
$0.97vs$0.93
Q4 25
+32.5%
$1.02vs$0.77
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 4, 2026 | $0.90 | — | — | — |
Q4 2025 | Nov 5, 2025 | $0.77 | $1.02 | +32.5% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $0.93 | $0.97 | +4.3% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $0.92 | $0.92 | 0.0% | = MET |
Q1 2025 | Feb 5, 2025 | $0.88 | $0.91 | +3.4% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $0.87 | $0.88 | +1.4% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $0.70 | $0.66 | -5.9% | ✗ MISS |
Q2 2024 | May 2, 2024 | $0.74 | $0.82 | +10.5% | ✓ BEAT |
Q1 2024 | Jan 31, 2024 | $0.65 | $0.71 | +9.5% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $0.71 | $0.71 | 0.0% | = MET |
Q3 2023 | Aug 10, 2023 | $0.67 | $0.63 | -6.0% | ✗ MISS |
Q2 2023 | May 4, 2023 | $0.63 | $0.63 | 0.0% | = MET |
Q1 2023 | Feb 1, 2023 | $0.41 | $0.41 | 0.0% | = MET |
Q4 2022 | Nov 2, 2022 | $0.42 | $0.43 | +2.4% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $0.44 | $0.42 | -4.5% | ✗ MISS |
Q2 2022 | Apr 29, 2022 | $0.43 | $0.47 | +9.3% | ✓ BEAT |
Q1 2022 | Feb 2, 2022 | $0.35 | $0.37 | +5.7% | ✓ BEAT |
Q4 2021 | Nov 3, 2021 | $0.40 | $0.42 | +5.0% | ✓ BEAT |
Q3 2021 | Aug 4, 2021 | $0.38 | $0.43 | +13.2% | ✓ BEAT |
Latest News
President Trump Says The 3 Of The 17 Pharmaceutical Companies Who Have Not Agreed Are Coming In Next Week
➖ NeutralBenzinga•Dec 19, 2025, 07:30 PM•Also: , ,
Novo Nordisk Submits New Drug Application To U.S. FDA For Once-Weekly Cagrisema Injection
📈 PositiveBenzinga•Dec 18, 2025, 01:19 PM
Novo Nordisk Says EMA Issues Positive Opinion For New Wegovy 7.2 mg Dose, Supporting Substantial Weight Loss In STEP UP Programme
📈 PositiveBenzinga•Dec 12, 2025, 02:01 PM
Argus Research Downgrades Novo Nordisk to Hold
📉 NegativeBenzinga•Dec 8, 2025, 01:20 PM
4 stocks to watch on Thursday: NVO, PLTR, DG, PSKY
➖ NeutralSeeking Alpha•Dec 4, 2025, 01:59 PM•Also:
'Novo Nordisk gears up for December Ozempic launch in India, sources say' - Reuters
📈 PositiveBenzinga•Dec 3, 2025, 05:57 PM
Akero Therapeutics Shareholders Approved Proposed Takeover By Novo Nordisk
📈 PositiveBenzinga•Dec 3, 2025, 03:46 PM•Also:
Omeros Closes Asset Purchase And License Agreement With Novo Nordisk For OMS906; Omeros Eligible For Upfront And Near-Term Milestones Up to $340M, of which $240M Was Paid In Cash At Closing, With Omeros Eligible For Up to $2.1B In Milestones And Royalties
📈 PositiveBenzinga•Dec 1, 2025, 01:35 PM•Also:
Goldman Sachs Maintains Buy on Novo Nordisk, Lowers Price Target to $54
➖ NeutralBenzinga•Nov 28, 2025, 01:33 PM
Reported Earlier: Novo Nordisk Submits Supplemental New Drug Application To U.S. FDA For Higher Dose Of Semaglutide Injection 7.2 Mg
📈 PositiveBenzinga•Nov 26, 2025, 04:37 PM
BMO Capital Maintains Market Perform on Novo Nordisk, Lowers Price Target to $46
📉 NegativeBenzinga•Nov 25, 2025, 01:22 PM
Novo Nordisk shares are trading higher after the company reported Phase 2 data showing up to 14.5% weight loss at 36 weeks for Amycretin.
📈 PositiveBenzinga•Nov 25, 2025, 12:27 PM
Novo Nordisk Announced Amycretin Showed Statistically Significant Weight Loss Of Up To 14.5% At 36 Weeks In Phase 2 Trial
📈 PositiveBenzinga•Nov 25, 2025, 11:27 AM
HSBC Downgrades Novo Nordisk to Hold
📉 NegativeBenzinga•Nov 24, 2025, 03:53 PM•Also:
Biogen shares are trading higher after Novo Nordisk's Evoke Phase 3 trials did not show a statistically significant reduction in Alzheimer's disease progression.
📈 PositiveBenzinga•Nov 24, 2025, 12:48 PM•Also: ,
Market-Moving News for November 24th
➖ NeutralBenzinga•Nov 24, 2025, 12:41 PM•Also: ,
Novo Nordisk slides as Ozempic pill fails to slow Alzheimer's disease progression in large trials
📉 NegativeSeeking Alpha•Nov 24, 2025, 11:52 AM
Novo Nordisk shares are trading lower after Evoke Phase 3 trials data showed that GLP-1 drugs did not demonstrate statistically significant reduction in Alzheimer's disease progression.
📉 NegativeBenzinga•Nov 24, 2025, 11:46 AM•Also:
Novo Nordisk Announced Evoke Phase 3 Trials Did Not Demonstrate Statistically Significant Reduction In Alzheimer's Disease Progression
📉 NegativeBenzinga•Nov 24, 2025, 11:26 AM•Also:
Bloomberg Reported Novo Nordisk, Eli Lilly Will Offer Zepbound, Wegovy Direct To Employers Starting Jan. 1
📈 PositiveBenzinga•Nov 21, 2025, 12:31 PM•Also:
Frequently Asked Questions about NVO
What is NVO's current stock price?
Novo Nordisk A/S (NVO) is currently trading at $48.09 per share. The stock has moved +1.01% today.
What is the analyst price target for NVO?
The average analyst price target for NVO is $52.33, based on 1 analyst.
What sector is Novo Nordisk A/S in?
Novo Nordisk A/S operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. The company is traded on the NYSE exchange.
What is NVO's market cap?
Novo Nordisk A/S has a market capitalization of $213.76 billion, making it a mega-cap company.
Does NVO pay dividends?
No, Novo Nordisk A/S does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABT
Abbott Laboratories
$125.42
Mkt Cap: $218.3B
AMGN
Amgen Inc.
$327.38
Mkt Cap: $176.3B
AZN
AstraZeneca PLC
$91.36
Mkt Cap: $283.3B
GILD
Gilead Sciences, Inc.
$124.29
Mkt Cap: $154.2B
GSK
GSK plc
$48.61
Mkt Cap: $98.8B
MRK
Merck & Co., Inc.
$101.09
Mkt Cap: $254.1B
NVS
Novartis AG
$136.06
Mkt Cap: $266.2B
PFE
Pfizer Inc.
$25.20
Mkt Cap: $143.3B
SNY
Sanofi
$48.18
Mkt Cap: $117.4B
TMO
Thermo Fisher Scientific Inc.
$567.83
Mkt Cap: $215.2B
Explore stocks similar to NVO for comparison